Literature DB >> 23432339

Pharmacokinetics of melatonin in preterm infants.

Nazakat M Merchant1, Denis V Azzopardi, Ahmed F Hawwa, James C McElnay, Benita Middleton, J Arendt, Tomoki Arichi, Pierre Gressens, A David Edwards.   

Abstract

AIMS: Preterm infants are deprived of the normal intra-uterine exposure to maternal melatonin and may benefit from replacement therapy. We conducted a pharmacokinetic study to guide potential therapeutic trials.
METHODS: Melatonin was administered to 18 preterm infants in doses ranging from 0.04-0.6 μg kg(-1) over 0.5-6 h. Pharmacokinetic profiles were analyzed individually and by population methods.
RESULTS: Baseline melatonin was largely undetectable. Infants receiving melatonin at 0.1 μg kg(-1)  h(-1) for 2 h showed a median half-life of 15.82 h and median maximum plasma concentration of 203.3 pg ml(-1) . On population pharmacokinetics, clearance was 0.045 l h(-1) , volume of distribution 1.098 l and elimination half-life 16.91 h with gender (P = 0.047) and race (P < 0.0001) as significant covariates.
CONCLUSIONS: A 2 h infusion of 0.1 μg kg(-1)  h(-1) increased blood melatonin from undetectable to approximately peak adult concentrations. Slow clearance makes replacement of a typical maternal circadian rhythm problematic. The pharmacokinetic profile of melatonin in preterm infants differs from that of adults so dosage of melatonin for preterm infants cannot be extrapolated from adult studies. Data from this study can be used to guide therapeutic clinical trials of melatonin in preterm infants.
© 2013 King's College, London. British Journal of Clinical Pharmacology © 2013 The British Pharmacological Society.

Entities:  

Keywords:  6-sulfatoxymelatonin; melatonin; neuroprotective agents; pharmacokinetics; preterm infants

Mesh:

Substances:

Year:  2013        PMID: 23432339      PMCID: PMC3853531          DOI: 10.1111/bcp.12092

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  41 in total

1.  Measurement of urinary melatonin: a useful tool for monitoring serum melatonin after its oral administration.

Authors:  J Kovács; W Brodner; V Kirchlechner; T Arif; F Waldhauser
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

2.  Cerebral white matter injury of the premature infant-more common than you think.

Authors:  Joseph J Volpe
Journal:  Pediatrics       Date:  2003-07       Impact factor: 7.124

3.  Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin.

Authors:  Eloisa Gitto; Russel J Reiter; Stefania P Cordaro; Mariangela La Rosa; Pietro Chiurazzi; Giuseppe Trimarchi; Placido Gitto; Maria P Calabrò; Ignazio Barberi
Journal:  Am J Perinatol       Date:  2004-05       Impact factor: 1.862

4.  Effects of melatonin treatment in septic newborns.

Authors:  E Gitto; M Karbownik; R J Reiter; D X Tan; S Cuzzocrea; P Chiurazzi; S Cordaro; G Corona; G Trimarchi; I Barberi
Journal:  Pediatr Res       Date:  2001-12       Impact factor: 3.756

5.  Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity.

Authors:  U Lang; M Kornemark; M L Aubert; L Paunier; P C Sizonenko
Journal:  J Clin Endocrinol Metab       Date:  1981-09       Impact factor: 5.958

6.  Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge.

Authors:  Isabelle Husson; Bettina Mesplès; Pierre Bac; Joseph Vamecq; Philippe Evrard; Pierre Gressens
Journal:  Ann Neurol       Date:  2002-01       Impact factor: 10.422

7.  Melatonin secretion occurs at a constant rate in both young and older men and women.

Authors:  J B Fourtillan; A M Brisson; M Fourtillan; I Ingrand; J P Decourt; J Girault
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-01       Impact factor: 4.310

8.  Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin.

Authors:  F Fulia; E Gitto; S Cuzzocrea; R J Reiter; L Dugo; P Gitto; S Barberi; S Cordaro; I Barberi
Journal:  J Pineal Res       Date:  2001-11       Impact factor: 13.007

9.  Melatonin reduces oxidative stress in surgical neonates.

Authors:  E Gitto; C Romeo; R J Reiter; P Impellizzeri; S Pesce; M Basile; P Antonuccio; G Trimarchi; C Gentile; I Barberi; B Zuccarello
Journal:  J Pediatr Surg       Date:  2004-02       Impact factor: 2.545

10.  Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin.

Authors:  Eloisa Gitto; Russel J Reiter; Aurelio Amodio; Carmelo Romeo; Elisabetta Cuzzocrea; Giuseppe Sabatino; Giuseppe Buonocore; Vincenzo Cordaro; Giuseppe Trimarchi; Ignazio Barberi
Journal:  J Pineal Res       Date:  2004-05       Impact factor: 13.007

View more
  17 in total

1.  Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study.

Authors:  H Aly; H Elmahdy; M El-Dib; M Rowisha; M Awny; T El-Gohary; M Elbatch; M Hamisa; A-R El-Mashad
Journal:  J Perinatol       Date:  2014-11-13       Impact factor: 2.521

Review 2.  Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct.

Authors:  Mark A Turner
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  Neuroprotection Strategies in Preterm Encephalopathy.

Authors:  Pratik Parikh; Sandra E Juul
Journal:  Semin Pediatr Neurol       Date:  2019-08-09       Impact factor: 1.636

Review 4.  The Safety of Melatonin in Humans.

Authors:  Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg; Russel J Reiter
Journal:  Clin Drug Investig       Date:  2016-03       Impact factor: 2.859

Review 5.  The fetus at the tipping point: modifying the outcome of fetal asphyxia.

Authors:  Simerdeep K Dhillon; Christopher A Lear; Robert Galinsky; Guido Wassink; Joanne O Davidson; Sandra Juul; Nicola J Robertson; Alistair J Gunn; Laura Bennet
Journal:  J Physiol       Date:  2018-06-21       Impact factor: 5.182

Review 6.  Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia.

Authors:  Daniel Alonso-Alconada; Antonia Alvarez; Olatz Arteaga; Agustín Martínez-Ibargüen; Enrique Hilario
Journal:  Int J Mol Sci       Date:  2013-04-29       Impact factor: 5.923

7.  Systemic and transdermal melatonin administration prevents neuropathology in response to perinatal asphyxia in newborn lambs.

Authors:  James D S Aridas; Tamara Yawno; Amy E Sutherland; Ilias Nitsos; Michael Ditchfield; Flora Y Wong; Rod W Hunt; Michael C Fahey; Atul Malhotra; Euan M Wallace; Graham Jenkin; Suzanne L Miller
Journal:  J Pineal Res       Date:  2018-03-25       Impact factor: 13.007

Review 8.  Protective role of melatonin in neonatal diseases.

Authors:  Eloisa Gitto; Lucia Marseglia; Sara Manti; Gabriella D'Angelo; Ignazio Barberi; Carmelo Salpietro; Russel J Reiter
Journal:  Oxid Med Cell Longev       Date:  2013-11-19       Impact factor: 6.543

Review 9.  Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy.

Authors:  Brandon J Dixon; Cesar Reis; Wing Mann Ho; Jiping Tang; John H Zhang
Journal:  Int J Mol Sci       Date:  2015-09-15       Impact factor: 5.923

10.  The Beneficial Effects of Melatonin Administration Following Hypoxia-Ischemia in Preterm Fetal Sheep.

Authors:  Tamara Yawno; Mawin Mahen; Jingang Li; Michael C Fahey; Graham Jenkin; Suzanne L Miller
Journal:  Front Cell Neurosci       Date:  2017-09-22       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.